PDCD1 and non-small cell lung carcinoma: Immunotherapy has caused a transformation in the TCR repertoire, with early changes in TCR clonality correlating with the immune response, thus influencing the clinical outcomes of anti-PD-1/PD-L1 treatment in NSCLC [33, 37–40].